A

Amgen

Makes biotech medicines for serious illnesses

Encryption Agility Service Lead

Full-TimeUpdated on 10/24/2026
No salary listed
Expert
Bachelor's, Master's, PhD, Associate's
Hyderabad, Telangana, India
In Person
CybersecuritySecurity Engineering & Architecture

About the job

Requirements
  • Doctorate degree and 2 years of experience in Information Security, Cybersecurity, Cryptography, Security Architecture, Computer Science, Information Technology, Engineering, or a related area; or master's degree with 8 to 10 years of such experience; or bachelor's degree with 10 to 14 years; or diploma with 14 to 18 years.
  • Expert knowledge of enterprise cryptography, including Public Key Infrastructure (PKI), X.509 certificates, Transport Layer Security (TLS), cipher suites, Key Management Services (KMS)/Hardware Security Modules (HSM), secrets management, key lifecycle, encryption at rest and in transit, and cloud key services.
  • Proven experience leading global information security, security architecture, or cryptography programs, including roadmap ownership, team management, resource planning, metrics, reporting, and executive stakeholder management.
  • Practical knowledge of post-quantum cryptography (PQC), crypto agility, National Institute of Standards and Technology (NIST)-approved algorithms and standards, hybrid/PQC transition patterns, cryptographic discovery, and Cryptographic Bill of Materials (CBOM)-driven remediation.
  • Ability to translate security policy into enforceable controls across Continuous Integration/Continuous Delivery (CI/CD), cloud platforms, identity, PKI/certificates, infrastructure, applications, third-party governance, and risk management.
  • CISSP certification is required.
  • Excellent people leadership, coaching, mentoring, and performance management skills.
  • Ability to translate complex cryptographic risk into clear business impact and action plans for executive stakeholders.
  • Strong verbal and written communication skills for technical, business, legal, procurement, compliance, and executive audiences.
  • Ability to influence without direct authority across global security, DTI, DIAS, procurement, legal, compliance, OT, infrastructure, and application teams.
  • Ability to exercise initiative, accountability, judgment, and self-motivation in ambiguous or evolving technical domains.
  • Ability to manage multiple priorities, competing stakeholder needs, and long-running transformation roadmaps.
  • Ability to balance hands-on technical analysis with service ownership, people leadership, and enterprise change management.
Responsibilities
  • Establish, operate, and continuously improve the enterprise Encryption Agility Team and Service, including the service charter, governance model, operating cadence, intake process, Responsible, Accountable, Consulted, and Informed (RACI) model, roadmap, Key Performance Indicators (KPIs), Key Risk Indicators (KRIs), executive reporting, and service improvement plan.
  • Lead, coach, mentor, and manage Encryption Agility Team members, including Amgen full-time employees, external workers, cryptographic engineers, security architecture analysts, product ownership support, and part-time contributors from partner teams.
  • Partner with the Principal Architect to translate enterprise PQC strategy into standards and specifications, reference architectures, implementation patterns, practical engineering guidance, remediation backlogs, and production-ready cryptographic design decisions.
  • Own the enterprise cryptographic standards and specifications roadmap, including approved algorithms, key sizes, protocols, TLS and cipher policies, certificate requirements, KMS and secrets requirements, exception criteria, RSA and Elliptic Curve Cryptography (ECC) sunset planning, and annual standards refresh.
  • Lead delivery across the full PQC lifecycle, including assessment wrap-up, quick wins, discovery tooling selection, iterative discovery, vendor and third-party outreach, PQC architecture, testing and trials, production rollout, automation, monitoring, and steady-state service operations.
  • Build, govern, and mature the Amgen CBOM, including required fields, asset ownership, quantum-vulnerability status, remediation status, data quality controls, reporting requirements, and integration of cryptographic inventory and risk data across relevant Amgen platforms.
  • Direct enterprise cryptographic discovery across source code, binaries, cloud key services, endpoints, file systems, network traffic, PKI and certificates, KMS and secrets, vendor attestations, and subject matter expert interviews to create a reliable enterprise cryptographic inventory.
  • Apply the approved PQC risk-prioritization approach to sequence discovery and remediation for business-critical applications, high-volume sensitive data flows, identity services, third-party dependencies, legacy platforms, Key Computerized Systems (KCS), and validated Good x Practice (GxP) systems.
  • Coordinate with DIAS, PKI service owners, certificate management teams, cloud, infrastructure, and platform teams on certificate visibility, Certificate Lifecycle Manager (CLM) evaluation, certificate rotation policy, manual-to-automated deployment migration, post-quantum PKI readiness, hybrid certificate testing, Certificate Authority (CA) roadmap, operational change windows, enterprise KMS strategy, HSM and cloud KMS roadmaps, secrets management, key rotation, key retirement, and centralized or federated key management control patterns.
  • Partner with Application Security, Secure Software Development Lifecycle (SSDLC), DevOps, Artificial Intelligence (AI) Security, Enterprise Architecture, and engineering teams to publish approved cryptographic libraries, reusable patterns, CI/CD controls, scanning rules, secure code examples, and remediation playbooks.
  • Coordinate with Risk and Compliance, Legal, Procurement, Third-Party Risk Management (TPRM), and vendor management to implement PQC questionnaires, CBOM requests, contract language, supplier roadmap tracking, risk acceptance, and executive escalation for vendors and Software as a Service (SaaS) providers.
  • Provide senior technical escalation and hands-on leadership for cryptographic standards exceptions, scan findings, false-positive triage, certificate outages, key and secret configuration issues, tool integration blockers, design tradeoffs, Steal-Now-Decrypt-Later (SNDL) exposure, identity and certificate risks, outdated TLS and cipher configurations, legacy cryptography, untracked keys, manual certificate processes, OT and manufacturing scope definition, developer and stakeholder enablement, and changes in NIST, Internet Engineering Task Force (IETF), National Security Agency Commercial National Security Algorithm (NSA/CNSA) Suite, International Organization for Standardization (ISO), Health Insurance Portability and Accountability Act (HIPAA), Health Information Trust Alliance (HITRUST), and industry cryptography guidance.
Desired Qualifications
  • CISM, CISA, or CRISC certification.
  • CCSP or a cloud security certification such as AWS Certified Security - Specialty or Azure Security Engineer.
  • TOGAF or SABSA certification.
  • ITIL, SAFe, product management, or program management certification.
  • Relevant PKI, KMS, HSM, cryptographic discovery, or certificate lifecycle management vendor certifications.
  • Hands-on experience with ServiceNow CMDB/GRC, Guard, Wiz, Qualys, Fortinet, Netskope, CrowdStrike, GitLab, Veracode, AWS KMS/ACM/Secrets Manager, Microsoft PKI, Sectigo, HashiCorp Vault, HSMs, CLM, and SIEM/data lake integrations.
  • Experience designing or operating CBOM/SBOM data models using CycloneDX 1.6+, APIs, CSV/JSON exports, dashboards, and data quality controls.
  • Experience coordinating PKI and certificate operations with DIAS or equivalent infrastructure and certificate service owners.
  • Experience in validated/GxP, manufacturing, OT, KCS, or highly regulated environments, including change control and revalidation impacts.
  • Experience with vendor and third-party risk management, supplier cryptographic questionnaires, contract requirements, and vendor roadmap tracking.
  • Scripting and automation experience with Python, PowerShell, Bash, REST APIs, or data pipeline tooling.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.